New Patents in Key International Markets Allow 1st-Level Verification in Seconds
STONY BROOK, N.Y.–(BUSINESS WIRE)–$apdn #anticounterfeiting–Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that brings integrity to global supply chains, and innovation to diagnostics and nucleic-based therapeutics, today announced the issuance of a Chinese patent and the receipt of a Notice of Allowability for a Canadian patent application, both for the invention “Encrypted Optical Markers for Security Applications” relating to its Beacon encrypted optical molecular marker technologies. The Company was previously granted United States Patent No. 10,047,282 on its Beacon technologies and has additional United States and international patent applications pending.
“China, Canada and the United States are key markets for our Beacon technology which provides formidable brand protection and assurance,” said Wayne Buchen, VP Strategic Sales. “The Company and its partners utilizing the Beacon technology, such as global sewing thread producer A&E, LLC and security label producer Schreiner MediPharm, are seeing strong customer interest in areas such as textiles, luxury goods and pharmaceutical packaging.”
The Beacon encrypted optical marker technology provides rapid, secure, real-time in-field authentication of a DNA-tagged substrate through the use of an encrypted fluorescing signal that can only be identified in the presence of a specially formulated decryptant. Without the paired decryptant, both Beacon and SigNature® DNA are invisible to normal and UV light. Based on its novel technology, we believe that Beacon is more secure than other non-encrypted chemical tracers that can be purchased on the open market and readily copied.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, our ability to successfully enter into commercial contracts for the implementation of our CertainT® platform, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and our subsequent quarterly report on Form 10-Q filed on February 6, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Contacts
Investor contact: Sanjay M. Hurry, 212-838-3777, LHA Investor Relations, shurry@lhai.com
Media Contact: John Shearman, 631-240-8838, john.shearman@adnas.com
Web: www.adnas.com
Twitter: @APDN